SynthesisAesthetic plastic surgery2026
Impact of Tranexamic Acid in Breast Plastic Surgery: A Systematic Review and Meta-Analysis.
Synthesis in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranexamic acid (TXA) is increasingly used in plastic surgery because of its effectiveness in reducing perioperative bleeding and enhancing recovery owing to its antifibrinolytic properties. We conducted a systematic review and meta-analysis to investigate TXA efficacy and safety in plastic breast surgery.
methodsA comprehensive literature search was performed using PubMed, Embase, Web of Science, and Cochrane CENTRAL databases, covering their inception period to the present and targeting randomized clinical trials and observational studies that met the predefined inclusion and exclusion criteria. Studies were screened for relevance, and data extraction focused on crucial variables. Effect estimates were pooled using random-effects models. The results are presented as odds ratios and corresponding 95% confidence intervals for primary (hematoma and seroma) and secondary (infection and duration of hospital stay) outcomes.
resultsEighteen studies involving 3,445 patients were included in the final meta-analysis. TXA administration caused substantial reductions in hematoma and seroma formation and notably reduced total hospital stay duration. No thromboembolic events or other serious complications were reported.
conclusionThe evidence from this study suggests that perioperative TXA administration significantly reduces the risk of complications in plastic breast surgery and shortens hospital stays, improving patient outcomes and resource utilization. Notably, the risk of thromboembolic events remains unchanged, validating TXA's safety and underscoring its value in standard perioperative protocols for plastic breast surgery procedures. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
41361151What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.